Novo Nordisk said it expects sales and profits to decline this year. The reason is growing competition in the market for obesity drugs, where Wego is facing increasing pressure. The company previously reported high revenue growth from Wegova, for example in the fourth quarter of last year by 107% to DKK 19.9 billion[1]. Total sales in the same period increased by 30% at constant exchange rates[1]. For this year, however, it expects slower sales growth of only 16 to 24% compared to the original estimate of 18 to 26%[1]. The slowdown is due to increasing competition and price pressure in the market for the treatment of diabetes and obesity[1]. In the US, pricing pressures have also hit Wego and Ozempic, including government price cuts for Medicare and Medicaid patients[5].